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Rhesus monkeys are protected from disease when a 
recombinant vesicular stomatitis virus–based vaccine is ad-
ministered 20–30 min after infection with Marburg virus. We 
protected 5/6 monkeys when this vaccine was given 24 h 
after challenge; 2/6 animals were protected when the vac-
cine was administered 48 h postinfection.
T
he ﬁ  loviruses, Marburg virus (MBGV) and Ebola virus 
(EBOV), have been associated with sporadic episodes 
of hemorrhagic fever (HF) in Central Africa that produce 
severe disease and high mortality rates among infected pa-
tients (1). MBGV and EBOV are also considered potential 
biological weapons. No approved active or passive thera-
peutic modalities exist for ﬁ  lovirus infections. Although 
much progress has been made in developing preventive 
vaccines that can protect nonhuman primates against lethal 
challenge with MBGV and EBOV, advances in develop-
ment of postexposure interventions against the ﬁ  lovirus-
es have not kept pace. Some degree of success has been 
achieved by using strategies that mitigate the coagulation 
abnormalities characterizing ﬁ  loviral infection (2,3). Also, 
new postexposure treatment approaches, based on small 
interfering RNA (4) and antisense oligomers (5,6), have 
shown promising results in rodent models, but no reports 
have been published of evaluations of either strategy in the 
more stringent macaque models.
Recently, we showed the ﬁ  rst complete postexposure 
protection of nonhuman primates against a ﬁ  lovirus by ad-
ministering a live-attenuated recombinant vesicular stoma-
titis virus (rVSV) vaccine vector expressing the MBGV 
glycoprotein (GP) (VSVΔG MBGV GP) shortly after a 
high-dose MBGV challenge (7,8). We demonstrated that 
an rVSV vector, expressing the Zaire EBOV (ZEBOV) 
GP, protected 50% of rhesus macaques when administered 
shortly after a high-dose ZEBOV challenge (9). We further 
showed that an rVSV vector expressing the Sudan EBOV 
GP completely protected rhesus monkeys from a lethal chal-
lenge with this virus when administered shortly after expo-
sure (10). All animals in these 3 studies were treated once 
with rVSV vectors 20–30 min after ﬁ  lovirus challenge. The 
primary question raised from these investigations is how 
far out treatment can be delayed before there is no survival 
or beneﬁ  cial effect. Using a homologous VSVΔG MBGV 
GP vector, we have delineated a window of opportunity for 
treatment of MBGV-infected rhesus macaques.
The Study
Animal research was conducted in compliance with 
the Animal Welfare Act and other federal statutes and 
regulations relating to animals and experiments involving 
animals and adhered to the principles stated in the Guide 
for the Care and Use of Laboratory Animals, National 
Research Council, 1996. Fifteen healthy, ﬁ  lovirus-serone-
gative rhesus macaques (each weighing 4 kg–7 kg) were 
randomized into 2 experimental groups of 6 monkeys per 
group and 3 control groups of 1 animal per group. All 15 
animals were challenged by intramuscular (IM) injection 
with 1,000 PFU of MBGV (Musoke strain). Approximately 
24 h after MBGV challenge, animals in experimental group 
1 received a single IM injection of VSVΔG MBGV GP (≈2 
× 107 PFU) (8), and the animal in control group 1 received 
an equal dose of a VSV vector encoding a nonrelated GP 
(VSVΔG/LassaGPC). Approximately 48 h after MBGV 
challenge, animals in experimental group 2 received a sin-
gle IM injection of VSVΔG MBGV GP (≈2 × 107 PFU), 
and the animal in control group 2 received an equal dose 
of VSVΔG/LassaGPC. The animal in control group 3 was 
not treated. Blood samples for viral infectivity titration, re-
verse transcription–PCR (RT-PCR), hematologic analysis, 
serum biochemical analysis, and immunoglobulin (Ig) G 
were collected before MBGV challenge and on days 3, 6, 
10, 14, and 31–35 after MBGV challenge.
Five of the 6 animals treated with VSVΔG/MBGV GP 
24 h after MBGV challenge (animals 1, 2, 4–6) and 2 of the 6 
animals treated with VSVΔG/MBGV GP 48 h after MBGV 
challenge (animals 7 and 10) survived (Figure; online Ap-
pendix Table, www.cdc.gov/EID/content/16/7/1119-appT.
htm). In contrast, symptoms consistent with MBGV HF 
developed in 1 of the 6 macaques treated with VSVΔG/
MBGV GP at 24 h (animal 3) and in 4 of the 6 animals 
treated with VSVΔG/MBGV GP at 48 h (animals 8, 9, 
11, and 12); these included anorexia and a macular rash 
(Table 1). The 5 animals in which macular rash developed 
(animals 3, 8, 9, 11, and 12) also had plasma viremias 
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days 10–12 (Figure; Table 1; online Appendix Table). 
Symptoms developed in control animals 1–3 consistent 
with MBGV HF; each had plasma viremia levels >7.0 log10 
PFU/mL by day 10 and died on days 12, 12, and 11, respec-
tively (online Appendix Table).
Two of the 6 animals that survived MBGV challenge 
(animals 1 and 6) showed no change in appearance or be-
havior that indicated overt illness. Changes in hematolog-
ic results and/or blood parameters were observed in 5 of 
the surviving animals (2, 4, 5, 7, and 10) during the course 
of the study (online Appendix Table). Plaque assay and 
RT-PCR were unable to detect any evidence of MBGV in 
the plasma of 6 of the 7 surviving animals (1, 2, 4–6, and 
10). However, RT-PCR showed evidence of MBGV in 
peripheral blood mononuclear cells of 2 of these surviv-
ing animals (1 and 2) at day 10 (Table 2). Viremia of 4.2 
log10 PFU/mL developed on day 10 in 1 surviving ani-
mal (7) treated 48 h after infection, and RT-PCR showed 
evidence of MBGV in peripheral blood mononuclear cells 
of this animal on days 6 and 10. Viremia in plasma was 
cleared, and the animal showed little evidence of illness 
by day 14. The serologic response proﬁ  le of MBGV in-
fection after treatment was evaluated by IgG ELISA. All 
7 animals that were treated with VSV∆G/MBGV GP and 
survived infection showed moderate to high levels of IgG 
by day 14 (320–1,000); humoral response against MBGV 
was not detectable in the treated animals that died or in 
the control animals (Table 2).
Conclusions
This rhesus macaque model represents a worse-case 
scenario such as an accidental needle-stick exposure of a 
laboratory worker or ﬁ  rst responder to a high infectious 
dose of a ﬁ  lovirus. Accidents such as these have occurred 
several times over the past 5 years (11–13). Of direct rel-
evance to our study was a recent laboratory accident in 
which an rVSV vector expressing the ZEBOV GP, which 
had been used successfully in postexposure treatment of 
experimentally infected nonhuman primates (9), was ad-
ministered to a human ≈40 h after a ZEBOV needle-stick 
exposure (13). The patient received a dose of ≈5 × 107 PFU 
of the VSV ZEBOV GP vaccine, which is consistent with 
doses used in nonhuman primate studies (7,9,10). Fever, 
headache, and myalgia developed in the patient hours after 
injection but were successfully controlled with analgesics 
and antipyretics. Other adverse effects were not reported, 
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Figure. Survival curves for Marburg virus–infected rhesus 
macaques treated 24 or 48 h after challenge with a recombinant 
vesicular stomatitis virus vaccine.
Table 1. Viral load in rhesus monkeys after Marburg virus challenge* 
Animal no. Group Treatment
Time of treatment 
after challenge, h
Plasma† PBMC
Day 6 Day 10 Day 14 Day 6 Day 10 Day 14
1 Exp 1  VSV-Marburg  24 0 (–)  0 (–)  0 (–)  NT (–)  NT (+)  NT
2 Exp 1  VSV-Marburg  24 0 (–)  0 (–)  0 (–)  NT (–)  NT (+)  NT (–) 
3 Exp 1  VSV-Marburg  24 3.76 (–)  6.19 (+)  NT (–)  NT (+) 
4 Exp 1  VSV-Marburg  24 0 (–)  0 (–)  0 (–)  NT (–)  NT (–)  NT (–) 
5 Exp 1  VSV-Marburg  24 0 (–)  0 (–)  0 (–)  NT (–)  NT (–)  NT (–) 
6 Exp 1  VSV-Marburg  24 0 (–)  0 (–)  0 (–)  NT (–)  NT (–)  NT (–) 
Control 1 Cont 1  VSV-Lassa 24 3.76 (–)  7.33 (+)  NT (–)  NT (+) 
7 Exp 2  VSV-Marburg  48 0 (–)  4.20 (+)  0 (–)  NT (+)  NT (+)  NT (–) 
8 Exp 2  VSV-Marburg  48 0 (–)  7.27 (+)  NT (+)  NT (+) 
9 Exp 2  VSV-Marburg  48 3.76 (–)  7.25 (+)  NT (+)  NT (+) 
10 Exp 2  VSV-Marburg  48 0 (–)  0 (–)  0 (–)  NT (–)  NT (–)  NT (–) 
11 Exp 2  VSV-Marburg  48 5.24 (+)  7.35 (+)  NT (+)  NT (+) 
12 Exp 2  VSV-Marburg  48 3.76 (–)  6.81 (+)  NT (–)  NT (+) 
Control 2 Cont 2  VSV-Lassa 48 4.05 (–)  7.24 (+)  NT (+)  NT (+) 
Control 3 Cont 3  None  NA 5.07 (+)  7.15 (+)  NT (+)  NT (+) 
*PBMC, peripheral blood mononuclear cells; Exp, experimental; VSV, vesicular stomatitis virus; NT, not tested; Cont, control; (+), sample positive for 
Marburg virus by reverse transcription–PCR (RT-PCR); (), sample negative for Marburg virus by RT-PCR; NA, not applicable. 
†Log10 PFU of Marburg virus per milliliter of plasma. Postexposure Treatment of Marburg Virus Infection
but whether treatment was effective or whether the patient 
never became infected remains uncertain.
MBGV infection of humans normally progresses at a 
slower rate than does MBGV infection of macaques, with 
case-fatality rates in humans of 23%–90% (1) suggesting 
that the therapeutic window may be larger for humans than 
for infected macaques. In addition, the challenge dose that 
we employed in the rhesus monkey model of MBGV HF 
of 1,000 PFU represents >10,000 LD50 doses (14), again 
showing that this is a robust challenge model. In the cur-
rent study, we achieved near complete protection from 
death when treatment with a single-dose regimen was 
delayed 24 h and 33% protection when treatment was de-
layed 48 h postexposure. Because no approved treatments 
exist for exposure to infectious ﬁ  loviruses, the rVSV vec-
tors described in the current study merit consideration for 
treating potential exposures and for further development 
for human use.
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Animal no. Group Treatment
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Serum anti–Marburg virus IgG†
Day 6 Day 10 Day 14
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3 Exp 1 VSV-Marburg 24 0 0 NA
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6 Exp 1 VSV-Marburg 24 0 320 320
Control 1 Cont 1 VSV-Lassa 24 0 0 NA
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9 Exp 2 VSV-Marburg 48 0 0 NA
10 Exp 2 VSV-Marburg 48 0 320 1,000
11 Exp 2 VSV-Marburg 48 0 0 NA
12 Exp 2 VSV-Marburg 48 0 0 NA
Control 2 Cont 2 VSV-Lassa 48 0 0 NA
Control 3 Cont 3 None NT 0 0 NA
*VSV, vesicular stomatitis virus; Ig, immunoglobulin; Exp, experimental group; Cont, control group; NA, not applicable because animal had died; NT, not 
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